CKM Syndrome Prevalence and Its Association With SCORE-2 and BRI
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age30-79
SponsorUniversity of Gaziantep
About this trial
This cross-sectional study aims to determine the prevalence of Cardiovascular-Kidney-Metabolic (CKM) syndrome in a community-based adult population in Gaziantep, Türkiye. In addition to estimating the prevalence across CKM stages, the study investigates the associations between CKM syndrome and two key risk indicators: the SCORE-2 cardiovascular risk score and Body Roundness Index (BRI). Findings from this study will provide valuable insights into early cardiometabolic risk profiling and support the development of regionally tailored prevention strategies.
Eligibility criteria
Qualifiers
None
Disqualifiers
None
Trial design
Treatments tested in this trial
- No intervention is applied. This is a non-interventional, observational study. Anthropometric measurements and existing laboratory data are used for CKM staging and risk assessment.
Treatment groups
400 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov